Emma Walmsley, chief executive of GSK, said: “GSK delivered another year of excellent performance in 2024, with strong sales and core profit growth driven by accelerating momentum of our specialty medicines portfolio.
GSK lifts long-term sales targets on new drug pipeline Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drug pipeline.
GSK said it expects core operating profits to rise by between 6% and 8% this year, with turnover said to lift by between 3% and 5%.
As a result, the company said it is targeting total sales of more than £40 billion by 2031, hiking its previous target of more than £38 billion.
It said it expects further growth to be boosted by its strong pipeline of new drugs, with 71 specialty medicines and vaccines now in clinical development.
